34747-57-4

Basic information

• Product Name: N-(4,6-dimethyl-2-pyrimidinyl)-4-morpholinecarboximidamide
• Synonyms: N-(4,6-dimethyl-2-pyrimidinyl)-4-morpholinecarboximidamide
• CAS NO: 34747-57-4
• Molecular Formula: C11H17N5O
• Molecular Weight: 235.28558
• Mol File: 34747-57-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4,6-dimethyl-2-pyrimidinyl)-4-morpholinecarboximidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4,6-dimethyl-2-pyrimidinyl)-4-morpholinecarboximidamide(34747-57-4)
• EPA Substance Registry System: N-(4,6-dimethyl-2-pyrimidinyl)-4-morpholinecarboximidamide(34747-57-4)

Safety Data

• Hazardous Substances Data: 34747-57-4(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 55474-90-3 (4,6-dimethylpyrimidin-2-yl)cyanamide 

Relevant articles and documents

Synthesis and anti-hyperglycemic evaluation of novel carboximidamides derived from cyanamides

Carboximidamides 4-10 and 4,5-dihydro-1H-imidazol-2-amines 11, 12 linked with pyrimidine moiety were obtained via reaction of N-(pyrimidin-2-yl)cyanamides 1-3 with amines such as; morpholine, piperidine, piperazines and/or ethylenediamine, respectively. N-(4,6-Dimethylpyrimidin-2-yl)morpholine-4-carboximidamide 4 is subjected to react with 4-methylbenzenesulphonyl-, benzoyl-, and/or terephthaloyl chloride to give the corresponding N-substituted carboximidamides 13-16. The structure of new compounds was confirmed by using FT-IR and NMR spectral data. X-ray single crystal diffraction analysis of 15 revealed that the structure belongs to the monoclinic system and has a chair conformation in a morpholine ring. DMSO and carboximidamides 6, 8 caused a significant decrease in the serum level of glucose, comparing with the diabetic-treated group (streptozotocin-treated group). Furthermore they restored the serum levels of ALT, AST, triglyceride and cholesterol (Biomarker of liver function) to the levels similar or slightly higher than of the negative control group. Also, the biomarkers of kidney function (serum urea and creatinine) were restored to the level urea or slightly higher than their negative control on the administration of DMSO and carboximidamides 6, 8. So it can be concluded that, DMSO and carboximidamides 6, 8 may be used as ameliorative agents against streptozotocin-induced a pathological effects on blood glucose, liver function and kidney function. Morever, it can be stated that these compounds may be more effective in reducing the pathological effects of streptozotocin-induced diabetes than that of metformin.